Cancer Treatment Reviews
Volume 31, Issue 6 , Pages 456-473 , October 2005

Tolerability and safety of rituximab (MabThera®)

  • Eva Kimby

      Affiliations

    • Corresponding Author InformationTel.: +46 8 58 58 00 00; fax: +46 8 7 74 87 25.

References 

  1. Johnson P, Glennie M. The mechanisms of action of rituximab in the elimination of tumor cells. Semin Oncol. 2003;30(Suppl. 2):3–8
  2. Roche Global Drug Safety database. Data on file, 2004.
  3. Bueno J, Ramil C, Somoza I, et al. Treatment of monomorphic B-cell lymphoma with rituximab after liver transplantation in a child. Pediatr Transplant. 2003;7:153–156
  4. Corbacioglu S, Eber S, Gungor T, Hummerjohann J, Niggli F. Induction of long-term remission of a relapsed childhood B-acute lymphoblastic leukemia with rituximab chimaeric anti-CD20 monoclonal antibody and autologous stem cell transplantation. J Pediatr Hematol Oncol. 2003;25:327–329
  5. Culic S, Culic V, Armanda V, Kuljis D, Pesutic-Pisac V, Jankovic S. Anti-CD20 monoclonal antibody (rituximab) for therapy of mediastinal CD20-positive large B-cell non-Hodgkin lymphoma with a local tumor extension into the lung of a 10-year-old girl. J Pediatr Hematol Oncol. 2003;20:339–344
  6. Herold M, Schnohr S, Bittrich H. Efficacy and safety of a combined rituximab chemotherapy during pregnancy. J Clin Oncol. 2001;19:3439
  7. Kimby E, Sverrisdottir A, Elinder G. Safety of rituximab therapy during the first trimester of pregnancy. Eur J Haematol. 2004;72:292–295
  8. MabThera® Summary of Product Characteristics (SmPC). URL: http://www.emea.eu.int/humandocs/PDFs/EPAR/Mabthera/025998en4.pdf (accessed July 2004).
  9. Rituxan® prescribing information. http://www.gene.com/gene/products/information/pdf/rituxan-prescribing.pdf (accessed July 2004).
  10. Maloney DG, Liles TM, Czerwinski DK, et al. Phase I trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood. 1994;84:2457–2466
  11. Maloney DG, Grillo-López AJ, White CA, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low grade non-Hodgkin’s lymphoma. Blood. 1997;90:2188–2195
  12. Maloney DG, Grillo-López AJ, White CA, et al. IDEC-CB8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin’s lymphoma. J Clin Oncol. 1997;15:3266–3274
  13. McLaughlin P, Grillo-López AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825–2833
  14. Hainsworth JD, Litchy S, Burris HA, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin’s lymphoma. J Clin Oncol. 2002;20:4261–4267
  15. Hainsworth JD, Litchey S, Morrissey L, et al. Rituximab as first-line and maintenance therapy for indolent non-Hodgkin’s lymphoma (NHL): long-term follow-up of a Minnie Pearl Cancer Research Network Phase II trial. Abstract 1496, updated in a poster presentation at the 45th Annual Meeting of the American Society of Hematology, December 6–9, 2003, San Diego, USA.
  16. Hainsworth JD, Litchy S, Barton JH, et al. Single agent rituximab as first-line and maintenance therapy for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2003;21:1746–1751
  17. Itala M, Geisler CH, Kimby E, et al. Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study. Eur J Haematol. 2002;69:129–134
  18. Ghielmini M, Schmitz S-F, Cogliatti S, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard 4-weekly schedule. Blood. 2004;103:4416–4423
  19. Hochster HS, Weller E, Ryan T, et al. Results of E1496: A Phase II trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL). Abstract 6502, updated in an oral presentation at the Annual Meeting of the American Society of Oncology, June 5–8, 2004, New Orleans, USA.
  20. Demidem A, Lam T, Alas S, et al. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm. 1997;12:177–186
  21. Alas S, Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin’s lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res. 2001;61:5137–5144
  22. Ghetie MA, Bright H, Vitetta ES. Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood. 2001;97:1392–1398
  23. Czuczman MS, Grillo-López AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimaeric anti CD-20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol. 1999;17:268–276
  24. Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-López AJ. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin’s lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol. 2004;22:4659–4664
  25. Coiffier B, Lepage E, Brière J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–242
  26. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus Rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2004 Oct 19 [Epub ahead of print].
  27. Czuczman MS, Fallon A, Mohr A, et al. Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. Semin Oncol. 2002;1(Suppl. 2):36–40
  28. Savage DG, Cohen NS, Hesdorffer CS, et al. Combined fludarabine and rituximab for low grade lymphoma and chronic lymphocytic leukemia. Leuk Lymphoma. 2003;44:477–481
  29. Byrd JC, Peterson BL, Morrison VA, et al. randomized phase 2 study of fludarabine, with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukaemia Group B 9712 (CALGB 9712). Blood. 2003;101:6–14
  30. Byrd JC, Rai KR, Peterson BL, et al. The addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukaemia: an updated comparative analysis of CALGB 9712 and CALGB 9011. Blood 2004 May 11 [Epub ahead of print].
  31. Drapkin R, Di Bella NJ, Faragher DC, et al. Results of a Phase II multicenter trial of pentostatin and rituximab in Patients with low grade B-cell non-Hodgkin’s lymphoma: an effective and minimally toxic regimen. Clin Lymphoma. 2003;4:169–175
  32. Alas S, Bonavida B, Emmanouilides C. Potentiation of fludarabine cytotoxicity on non-Hodgkin’s lymphoma by pentoxifylline and rituximab. Anticancer Res. 2000;20:2961–2966
  33. McLaughlin P, Hagemeister F, Rodriguez M, et al. Safety of fludarabine, mitoxantrone and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma. Semin Oncol. 2000;27(Suppl. 12):37–41
  34. Jiang Y, McLaughlin P, Thomaides A, et al. Quantification and monitoring of the t (14; 18) translocation copy number by real-time PCR in patients with follicular lymphoma treated with FND plus concurrent or delayed rituximab. Abstract 1444, updated in a poster presentation at the 45th Annual Meeting of the American Society of Hematology, December 6–9, 2003, San Diego, USA.
  35. Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival compared to FCM alone in patients with relapsed and refractory follicular and mantle cell lymphoma – results of a prospective randomized studyBlood. Blood. 2004;104:3064–3071
  36. Davis TA, Maloney DG, Grillo-López AJ. Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin’s lymphoma with rituximab and interferon-alpha-2a. Clin Cancer Res. 2000;6:2644–2652
  37. Kimby E, Geisler C, Hagberg H, et al. Rituximab (MabThera) as a single agent and in combination with interferon-alpha-2a as treatment of untreated and first relapse follicular or other low-grade lymphomas. A randomized phase II study M 39035. Blood. 2000;96(Suppl. 1):A2479
  38. Kimby E, Geisler C, Hagberg H, et al. Rituximab (MabThera) as a single agent and in combination with interferon-alpha-2a as treatment of untreated and first relapse follicular or other low-grade lymphomas. A randomized phase II study M 39035. Ann Oncol. 2002;13(Suppl. 2):85;(Abstr 289)
  39. Sacchi S, Federico M, Vitolo U, et al. Clinical activity and safety of combination immunotherapy with IFN-alpha2a and rituximab in patients with relapsed low grade non-Hodgkin‘s lymphoma. Haematologica. 2001;86:951–958
  40. Friedberg JW, Neuberg D, Gribben JG, et al. Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin’s lymphoma. Br J Haematol. 2002;117:828–834
  41. Gluck WL, Hurst D, Yuen A, et al. Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-Hodgkin’s lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clin Cancer Res. 2004;10:2253–2264
  42. Ansell SM. Adding cytokines to monoclonal antibody therapy: does the concurrent administration of interleukin-12 add to the efficacy of rituximab in B-cellnon-Hodgkin lymphoma?. Leuk Lymphoma. 2003;44:1309–1315
  43. van der Kolk LE, Grillo-Lopez AJ, Baars JW, et al. Treatment of relapsed B-cell non-Hodgkin’s lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy. Leukemia. 2003;17:1658–1664
  44. Dillman R. Treatment of low-grade B-cell lymphoma with the monoclonal antibody rituximab. Semin Oncol. 2003;30:434–437
  45. Gisselbrecht C, Mounier N. Rituximab: enhancing outcome of autologous stem cell transplantation in non-Hodgkin’s lymphoma. Semin Oncol. 2003;30:28–33
  46. Goldberg SL, Pecora AL, Jennis AA, et al. Rituximab permits in -vivo purging and collection of tumor free stem cells prior to autologous transplantation in B-cell non-Hodgkin’s lymphoma. Blood. 1999;94(Suppl. 1):141a
  47. Salles G, Moullet I, Charlot C, et al. In vivo purging with rituximab before autologous peripheral blood progenitor cell (PBSC) transplantation in lymphoma patients (PTS). Blood. 1999;94(Suppl. 1):141a
  48. Buckstein R, Imrie K, Spaner D, et al. Stem cell function and engraftment is not affected by “in vivo purging” with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin’s lymphoma. Semin Oncol. 1999;26(Suppl. 14):115–122
  49. Magni M, Di Nicola M, Devizzi L, et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood. 2000;96:864–869
  50. Haioun C, Delfau-Larue MH, Beaujean F, et al. Efficiency of in vivo purging with rituximab followed by high-dose therapy (HDT) with autologous peripheral blood stem cell transplantation (PBSCT) in B-cell non-Hodgkin’s lymphomas (NHL). A single institution study. Blood. 2000;96:184a
  51. Gianni AM, Cortelazzo S, Magni M, Martelli M. Michelangelo Cooperative. Rituximab: enhancing stem cell transplantation in mantle cell lymphoma. Bone Marrow Transplant. 2002;29(Suppl. 1):S10–S13
  52. Belhadj K, Delfau-Larue M-H, Elgnaoui T, et al. Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cell non-Hodgkin’s lymphoma: a single institution study. Ann Oncol. 2004;15:504–510
  53. Arcaini L, Orlandi E, Alessandrino EP, et al. A model of in vivo purging with rituximab and high-dose AraC in follicular and mantle cell lymphoma. Bone Marrow Transplant. 2004;34:175–179
  54. Haioun C, Mounier N, Emile JF, et al. Interim analysis of the randomized LNH98-B3 GELA study. Abstract 1447, updated in a poster presentation at the 45th Annual Meeting of the American Society of Hematology, December 6–9, 2003, San Diego, USA.
  55. Horwitz SM, Negrin RS, Blume KG, et al. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood. 2004;103:777–783
  56. Buckstein RJ, Mangel JJ, Imrie K, et al. High-dose therapy/ASCT consolidated by rituximab and/or interferon immunotherapy for relapsed follicular lymphoma achieves durable molecular remissions and improved progression-free survival. Blood. 2003;102(11):A5692
  57. Flinn IW, Diehl LF, Garrett E, et al. Rituximab and peripheral blood stem cell transplantation produces durable remissions in patients with low grade and mantle cell lymphoma. Abstract 869, updated in an oral presentation at the 45th Annual Meeting of the American Society of Hematology, December 6–9, 2003, San Diego, USA.
  58. Mangel J, Leitch HA, Connors JM, et al. Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle cell lymphoma: a matched pair analysis. Ann Oncol. 2004;15:283–290
  59. Kewalramani T, Zelenetz AD, Nimer SD, et al. Rituximab and ICE (RICE) as second-line therapy prior to autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2004;103:3684–3688
  60. Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood. 1988;71:117–122
  61. Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP–an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol. 1994;12:1169–1176
  62. Amar-Maman D, Mounier N, Manson J, et al. Evaluation of efficacy and toxicity of rituximab plus aracytin-platinum (R-DHAP) regimen in non-Hodgkin lymphoma (NHL) relapsing patients. Blood. 2002;100:A293
  63. Moskowitz CH, Bertino JR, Glassman JR, et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin’s lymphoma. J Clin Oncol. 1999;17:3776–3785
  64. Edwards JCW, Szczepański L, Szechiński J, et al. Efficacy of B-cell targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350:2572–2581
  65. McLaughlin P, Hagemeister FB, Grillo-López AJ. Rituximab in indolent lymphoma: the single-agent pivotal trial. Semin Oncol. 1999;26(Suppl. 14):79–87
  66. Byrd JC, Murphy T, Howard RS, et al. Rituximab using a thrice-weekly dosing schedule in B-cell chronic lymphocytic leukaemia and small lymphocytic lymphoma demonstrated clinical activity and acceptable toxicity. J Clin Oncol. 2001;19:2153–2164
  67. Gaston RS, Deierhoi MH, Patterson T, et al. OKT3 first-dose reaction: association with T cell subsets and cytokine release. Kidney Int. 1991;39:141–148
  68. Wing MG, Moreau T, Greenwood J, et al. Mechanism of first-dose cytokine-release syndrome by Campath 1-H: Involvement of Cd16 (Fc γ RIII) and CD11a/CD18 (LFA-1) on NK cells. J Clin Invest. 1996;98:2819–2823
  69. Lim LC, Koh LP, Tan P. Fatal cytokine release syndrome with chimeric anti-CD20 monoclonal antibody rituximab in a 71-year-old patient with chronic lymphocytic leukemia. J Clin Oncol. 1999;17:1962–1963
  70. Byrd JC, Waselenko JK, Maneatis TJ, et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol. 1999;17:791–795
  71. Winkler U, Jensen M, Manzke O, et al. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood. 1999;94:2217–2224
  72. O’Brien SM, Kantarjian AH, Thomas DA, et al. Rituximab dose-escalation in chronic lymphatic leukaemia. J Clin Oncol. 2001;19:2165–2170
  73. Grillo-López AJ, Hedrick E, Rashford M, Benyunes M. Rituximab: ongoing and future clinical development. Semin Oncol. 2002;29(Suppl. 2):105–112
  74. Altman A. Acute tumor lysis syndrome. Semin Oncol. 2001;28(Suppl. 2):3–8
  75. Sallan S. Management of acute tumor lysis syndrome. Semin Oncol. 2001;28(Suppl. 2):9–12
  76. Cheson BD, Frame JN, Vena D, Quashu N, Sorensen JM. Tumor lysis syndrome: an uncommon complication of fludarabine therapy of chronic lymphatic leukaemia. J Clin Oncol. 1998;16:2313–2320
  77. Hande KR, Garrow GC. Acute tumor lysis syndrome in patients with high-grade non-Hodgkin’s lymphoma. Am J Med. 1993;94:133–139
  78. Lin TS, Lucas MS, Byrd JC. Rituximab in B-cell chronic lymphatic leukemia. Semin Oncol. 2003;30:483–492
  79. Cheson BD. Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol. 1995;13:2431–2438
  80. Kimby E, Brandt L, Nygren P, et al. A systematic overview of chemotherapy effects in aggressive non-Hodgkin’s lymphoma. Acta Oncol. 2001;40:198–212
  81. Wierda W, O’Brien S, Cortes J, et al. Update of results of the combination of fludarabine, cyclophosphamide and rituximab for previously untreated patients with chronic lymphocytic leukaemia (CLL). Blood. 2001;98:A3210
  82. Saikia TK, Menon H, Advani SH. Prolonged neutropenia following anti CD20 therapy in a patient with relapsed follicular non-Hodgkin’s lymphoma and corrected with IVIG. Ann Oncol. 2001;12:1493–1494
  83. Chaiwatanatorn K, Lee N, Grigg A, Filshie R, Firkin F. Delayed-onset neutropenia associated with rituximab therapy. Br J Haematol. 2003;121:913–918
  84. Voog E, Morschhauser F, Solal-Céligny P. Neutropenia in patients treated with rituximab. N Engl J Med. 2003;348:2691–2694
  85. Cairoli R, Grillo G, Tedeschini A, Avanzo G, Marenco P, Morra E. High incidence of neutropenia in patients treated with rituximab after autologous stem cell transplantation. Haematologica. 2004;89:361–363
  86. Lernieux B, Tartas S, Traulle C, et al. Rituximab-relayed late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin’s lymphoma. Bone Marrow Transplantation. 2004;33:921–923
  87. Belhadj K, Doghmi K, El Gnaoui T, et al. Delayed severe neutropenia after rituximab therapy in 12 out of 282 patients with non-Hodgkin’s lymphoma treated in a single institution: a rare adverse event of unknown mechanism. Abstract 029 presented at the 9th Meeting of the European Haematology Association, Geneva, Switzerland, June 2004.
  88. Rose AL, Forsythe AM, Maloney DG. Agranulocytosis unresponsive to growth factors following in vivo purging. Blood. 2003;101:4225
  89. Cattaneo C, Spedini P, Riggeri G et al. Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments. Abstract 024 presented at the 9th Meeting of the European Haematology Association, Geneva, Switzerland, June 2004.
  90. Brasca P, Cairoli R, Grillo G, et al. High incidence of neutropenia in patients treated with rituximab after autologous stem cell transplantation. Abstract 145 presented at the 9th Meeting of the European Haematology Association, Geneva, Switzerland, June 2004.
  91. Papadaki T, Stamatopoulos K, Stavroyianni N, Paterakis G, Phisphis M, Stefanoudaki-Sofianatou K. Evidence for T-large granular lymphocyte-mediated neutropenia in rituximab-treated lymphoma patients: report of two cases. Leuk Res. 2002;26:597–600
  92. Weng W-K, Horning SJ, Negrin RS, Levy R. Immunoglobulin G Fc polymorphisms is correlated with rituximab-induced neutropenia following autologous hematopoietic cell transplantation. Abstract 442, updated in an oral presentation at the 46th Annual Meeting of the American Society of Hematology, December 4–7, 2004, San Diego, USA.
  93. Benyunes MC, Multani PS, Saunders A. Neutropenia in patients treated with rituximab. [Response to Voog et al. 2003] N Engl J Med. 2003;348:2694
  94. Battle M, Ribera JM, Oriol A, et al. Successful response to rituximab in a patient with pure red cell aplasia complicating chronic lymphocytic leukaemia [letter]. Br J Haematol. 2002;118:1192–1193
  95. Auner HW, Wolfler A, Beham-Schmid C, Strunk D, Linkesch W, Sill H. Restoration of erythropoiesis by rituximab in an adult patient with primary acquired pure red cell aplasia refractory to conventional treatment [letter]. Br J Haematol. 2002;116:727–728
  96. Zecca M, De Stefano P, Nobili B. Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated pure red cell aplasia and hemolytic anemia. Blood. 2001;97:3995–3997
  97. Ghazal H. Successful treatment of pure red cell aplasia with rituximab in patients with chronic lymphocytic leukemia. Blood. 2002;99:1092–1094
  98. Davis TA, White CA, Grillo-López AJ, et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin’s lymphoma: results of a Phase II trial of rituximab. J Clin Oncol. 1999;17:1851–1857
  99. Piro LT, White CA, Grillo-López AJ, et al. Extended rituximab (anti CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin’s lymphoma. Ann Oncol. 1999;10:655–661
  100. Davis TA, Grillo-López AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin’s lymphoma: safety and efficacy of re-treatment. J Clin Oncol. 2000;18:3135–3143
  101. Lemieux B, Bouafia F, Thieblemont C, et al. Second treatment with rituximab in B-cell non-Hodgkin’s lymphoma: efficacy and toxicity on 41 patients treated at CHU-Lyon Sud. Hematology J. 2004;5:467–471
  102. Song KW, Mollee P, Patterson B, et al. Pure red cell aplasia due to parvovirus following treatment with CHOP and rituximab for B-cell lymphoma. Br J Haematol. 2002;119:125–127
  103. Bermudez A, Marco F, Conde E, Mazo E, Recio M, Zubizarreta A. Fatal visceral varicella-zoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma. Haematologica. 2000;85:894–895
  104. Hernandez JA, Diloy R, Salat D, et al. Fulminant hepatitis subsequent to reactivation of precore mutant hepatitis B virus in a patient with lymphoma treated with chemotherapy and rituximab. Haematologica. 2003;88:22
  105. Westhoff TH, Jochimsen F, Schmittel A, et al. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood. 2003;102:1930
  106. Hamaki T, Kami M, Kusumi E, et al. Prophylaxis of hepatitis B reactivation using lamivudine in a patient receiving rituximab. Am J Hematol. 2001;68:292–294
  107. Kami M, Hamaki T, Murashige N, et al. Safety of rituximab in lymphoma patients with hepatitis B or hepatitis C virus infection. Hematol J. 2003;4:159–162
  108. Klepfish A, Stationer A, Shvidel L, et al. Successful treatment of aggressive HIV-associated non-Hodgkin’s lymphoma with combination chemotherapy, biotherapy with rituximab and HAART: presentation of a therapeutic option. Leuk Lymphoma. 2003;44:349–351
  109. Maeda T, Yamada Y, Tawara M, et al. Successful treatment with a chimeric anti-CD20 monoclonal antibody (IDEC C2-B8, rituximab) for a patient with relapsed mantle cell lymphoma who developed a human anti-chimeric antibody. Int J Hematol. 2001;74:70–75
  110. D’Arcy CA, Mannik M. Serum sickness secondary to treatment with the murine–human chimaeric antibody IDEC-C2B8 (rituximab). Arthritis Rheum. 2001;44:1717–1718
  111. Herishanu Y. Rituximab-induced serum sickness. Am J Hematol. 2002;70:329
  112. Hellerstedt B, Ahmed A. Delayed-type hypersensitivity reaction or serum sickness after rituximab treatment. Ann Oncol. 2003;14:1792
  113. Schmitz K, Brugger W, Weiss B, et al. Clonal selection of CD20-negative non-Hodgkin’s lymphoma cells after treatment with anti-CD20 antibody rituximab. Br J Haematol. 1999;106:571–572
  114. Davis TA, Czerwinski DK, Levy R, et al. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin Cancer Res. 1999;5:611–615
  115. Kennedy GA, Tey S-K, Cobcrift R, et al. Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin’s lymphoma: a retrospective review. Br J Haematol. 2002;119:412–416
  116. Massengale WT, McBurney E, Gurtler J. CD20-negative relapse of cutaneous B-cell lymphoma after anti-CD20 monoclonal antibody therapy. J Am Acad Dermatol. 2002;46:441–443
  117. Clarke LE, Bayerl MG, Ehmann WC, Helm KF. Cutaneous B-cell lymphoma with loss of CD20 immunoreactivity after rituximab therapy. J Cutan Pathol. 2003;30:459–462
  118. Haidar JH, Shamseddine A, Salem Z, et al. Loss of CD20 expression in relapsed lymphomas after rituximab therapy. Eur J Haematol. 2003;70:330–332
  119. Foran JM, Norton AJ, Micallef IN, Foran JM, Rohatiner AZ, Lister TA. Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): a retrospective cohort analysis. Br J Haematol. 2001;114:881
  120. Chu PG, Arber DA. CD79: a review. Appl Immunohistochem Mol Morphol. 2001;9:97
  121. Jilani I, O’Brien S, Manshuri T, et al. Transient down-regulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. Blood. 2003;102:3514–3520
  122. Tetreault S, Abler SL, Robbins B, et al. Peripheral T-cell lymphoma after anti-CD20 antibody therapy. [published erratum appears in J Clin Oncol 1998;16:2001] J Clin Oncol. 1998;16:1635–1637
  123. Micallef IN, Kirk A, Norton A, et al. Peripheral T-cell lymphoma following rituximab therapy for B-cell lymphoma [Letter]. Blood. 1999;93:2427–2428
  124. Maloney DG, Davis T, Levy R. Peripheral T-cell lymphoma after anti-CD20 antibody therapy. J Clin Oncol. 1998;16:1636–1637
  125. Lowndes S, Darby A, Mead G. Stevens–Johnson syndrome after treatment with rituximab. Ann Oncol. 2002;13:1948–1950
  126. Heizmann M, Itin P, Wernli N, Borradori L, Bargetzi MJ. Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL. Am J Hematol. 2001;66:142–144
  127. Borradori L, Lombardi T, Samson J, Girardet C, Saurat JH, Hugli A. Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20+ follicular lymphoma-associated paraneoplastic pemphigus. Arch Dermatol. 2001;137:269–272
  128. Schadlow MB, Anhlat GJ, Sinha AA. Using rituximab (anti-CD20 antibody) in a patient with paraneoplastic pemphigus. J Drugs Dermatol. 2003;2:564–567
  129. Kanelli S, Ansell SM, Habermann T, Inwards DI, Tuinstra N, Witzig TE. Rituximab toxicity in patients with peripheral blood malignant B-cell lymphocytosis. Leuk Lymphoma. 2001;42:1329–1337
  130. Burton C, Kaczmarski R, Jan-Mohamed R. Interstitial pneumonitis related to rituximab therapy. N Engl J Med. 2003;348:2690–2691
  131. Julien V, Perrin C, Peyrade F, Lemoigne F, Chichmanian RM, Blaive B. A case of acute respiratory failure related to rituximab therapy. Rev Mal Respir. 2004;21:407–410
  132. Swords R, Power D, Fay M, O’Donnell R, Murray PT. Interstitial pneumonia following rituximab therapy for immune thrombocytopenic purpura. Am J Hematol. 2004;77:103–104
  133. Alexandrescu DT, Ditcher JP, O’Boyle K, Albumet M, Oiseth S, Wiernek PH. Fatal intra-alveolar hemorrhage after rituximab in a patient with non-Hodgkin lymphoma. Leuk Lymphoma. 2004;45:2321–2325
  134. Hainsworth JD, Litchy S, Lamb MR, Rodriguez GI, Scroggin C, Greco FA. First-line treatment with brief-duration chemotherapy plus rituximab in elderly patients with intermediate-grade non-Hodgkin’s lymphoma: phase II trial. Clin Lymphoma. 2003;4:36–42
  135. Benyunes MC, Multani PS, Saunders A. Interstitial pneumonitis related to rituximab therapy. [Response to Burton et al. 2003] N Engl J Med. 2003;348:2691
  136. Vose JM, Link BK, Grossbard ML, et al. Long term follow-up of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated aggressive non-Hodgkin’s lymphoma. Abstract 1396, updated in a poster presentation at the 44th Annual Meeting of the American Society of Hematology, December 6–10, 2002, Philadelphia, USA.
  137. Coiffier B, Feugier P. Sebban C, et al. Long-term results of the GELA study: R-CHOP vs CHOP in elderly patients with diffuse large B-cell lymphoma. Abstract 1383, updated in a poster presentation at the 46th Annual Meeting of the American Society of Hematology, December 4–7, 2004, San Diego, USA.
  138. van der Kolk LE, Baars JW, Prins MH, et al. Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood. 2002;100:2257–2259
  139. Edwards JCW, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology. 2001;40:205–211
  140. Leandro MJ, Edwards JC, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis. 2002;61:883–888
  141. Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood. 2001;97:101–106
  142. Solal-Celigny P, Salles GA, Brousse N, et al. Single 4-dose rituximab treatment for low-tumor burden follicular lymphoma (FL): survival analyses with a follow-up of at least 5 years. Abstract 585, updated in an oral presentation at the 46th Annual Meeting of the American Society of Hematology, December 4–7, 2004, San Diego, USA.
  143. Hiddemann W, Forstpointner R, Kneba M, et al. Combined immuno-chemotherapy (R-CHOP) significantly improves time to treatment failure in first line therapy of follicular lymphoma. Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). Abstract 161, updated in an oral presentation at the 46th Annual Meeting of the American Society of Hematology, December 4–7, 2004, San Diego, USA.

PII: S0305-7372(05)00101-5

doi: 10.1016/j.ctrv.2005.05.007

Cancer Treatment Reviews
Volume 31, Issue 6 , Pages 456-473 , October 2005

Article Tools

* Image Usage & Resolution